A trial testing a drug combo before surgery for early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (Sacituzumab Govitecan and Tislelizumab) given before surgery to shrink early-stage triple-negative breast cancer. The goal is to see if a lower dose of treatment can still work well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage II or III triple-negative breast cancer that hasn't spread to other parts of the body.
- You are generally well enough to be active (ECOG 0-1) and your organs function normally (heart, liver, kidneys, blood, etc.).
- You haven't had any prior surgery, radiation, or chemotherapy for this breast cancer.
- You do not have active infections, autoimmune diseases, or other cancers that are still growing or need treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs given before surgery to treat early-stage triple-negative breast cancer that is PD-L1 positive. The goal is to see if the combination can shrink the tumor and improve outcomes.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery for triple-negative breast cancer (a type of breast cancer that lacks three common markers). The study aims to see if this treatment can shrink tumors and improve outcomes.
This clinical trial tests a new drug called Sacituzumab Tirumotecan given before surgery to women with an aggressive type of early-stage breast cancer (triple-negative breast cancer, or TNBC). The goal is to see if it can improve treatment outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
Hear when a new TNBC, Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.